B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
BHVN
BiohavenDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Resolution of the partial hold, a positive BHV7000-303 readout, and validating BHV-1530 data could restore confidence in opakalim while broadening pipeline value. BHV-1300 has also entered pivotal development in Graves' disease, providing a longer-duration source of optionality [#SEC-8K-2026-08-10].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -33.2.
What can break
BHV-1530 remains an early Phase 1 oncology asset, so limited-patient activity signals may not translate into durable efficacy.
Momentum
46
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $25.00 · Bear $6.00Analysis 2026-09-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $25.17
Why
Momentum46 · Δ7d +20.8
Value41 · Δ7d -0.0
Sentiment48 · Δ7d -33.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -33.2.
Contradictions & invalidation
- • BHV-1530 remains an early Phase 1 oncology asset, so limited-patient activity signals may not translate into durable efficacy.
- • Biohaven is advancing several clinical programs simultaneously, increasing execution and portfolio-prioritization risk [#SEC-8K-2026-08-10].
- • The partial hold introduces additional regulatory and development uncertainty shortly before the pivotal epilepsy readout.
Catalyst clock
2026-10-15
FDA partial-hold resolution for opakalim
Lead driver: Sentiment · See AI snapshot
Momentum
46
8% active weight
Current posture
7d trendImproving
Δ7d
+20.8
Δ21d
+13.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
48
45% active weight
Current posture
7d trendSoftening
Δ7d
-33.2
Δ21d
-18.1
Why this grade
Composite grade D. Momentum 45.8 / Value 40.6 / Sentiment 48.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-20. Scenario method
B
Base case
35%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
40%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$2.1B
Beta
3.56
Shares Out
151.04M
P/E (TTM) · Derived
-2.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.43
Rev YoY
-
EPS YoY
-52.9%
Gross Margin
-
Op Margin
-
Net Debt
-$35.3M
Current Ratio
4.73
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data